Aggressive FLC Escape in a Patient with IgD Myeloma.

Cédric Farges, Murielle Roussel, Anne Huynh, Antoine Blancher, Bénédicte Puissant-Lubrano

Abstract read

In one paragraph

Article in Case reports in hematology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Characterization and use of the novel human multiple myeloma cell line MC-B11/14 to study biological consequences of CRISPR-mediated loss of immunoglobulin A heavy chain.Experimental hematology · 2018
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Cédric FargesLaboratoire d'Immunologie, CHU de Toulouse, Hôpital Rangueil, 1 Avenue Jean Poulhès, TSA 50032, 31 059 Toulouse Cedex 9, France.

Murielle RousselHematology Department, University Hospital, 31059 Toulouse, France.

Anne HuynhHematology Department, University Hospital, 31059 Toulouse, France.

Antoine BlancherLaboratoire d'Immunologie, CHU de Toulouse, Hôpital Rangueil, 1 Avenue Jean Poulhès, TSA 50032, 31 059 Toulouse Cedex 9, France ; Laboratoire d'Immunogénétique Moléculaire (EA3034), Faculté de Médecine Toulouse-Rangueil, Université Paul Sabatier Toulouse III, Bâtiment A2, 133 route de Narbonne, 31062 Toulouse Cedex 04, France.

Bénédicte Puissant-LubranoLaboratoire d'Immunologie, CHU de Toulouse, Hôpital Rangueil, 1 Avenue Jean Poulhès, TSA 50032, 31 059 Toulouse Cedex 9, France ; Laboratoire d'Immunogénétique Moléculaire (EA3034), Faculté de Médecine Toulouse-Rangueil, Université Paul Sabatier Toulouse III, Bâtiment A2, 133 route de Narbonne, 31062 Toulouse Cedex 04, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background. Some patients who are stable or in remission from a myeloma secreting intact monoclonal immunoglobulin (+/- associated free light-chains (FLCs)) relapse with production of FLC. This FLC escape is one of the illustrations of the intraclonal heterogeneity of multiple myeloma. Results. We report FLC escape in a patient with IgD myeloma characterized by a severe outcome. We discuss parameters that negatively impacted prognosis in this patient, including bone lesions, biochemical parameters, and genomic abnormalities. Conclusion. This case illustrates the selective pressure exerted by therapeutic drugs and the variable sensitivity of subclones to these drugs; it also highlights the importance of FLC monitoring in treated MM patients.

Identifiers

PMID26640728

DOI10.1155/2015/694730

PMCPMC4657095

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.